Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | TACR3 | P29371 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1942507 | 1.00 | CTSB (0.53) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL1942057 | 0.98 | CTSB (0.55) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL1942687 | 0.98 | CTSB (0.55) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL1940779 | 0.98 | CTSB (0.55) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL1942948 | 0.98 | CTSB (0.55) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL6805061 | 0.94 | CTSB (0.56) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL6369432 | 0.92 | CTSB (0.57) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL6800080 | 0.92 | CTSB (0.57) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL6804142 | 0.92 | CTSB (0.58) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL6797924 | 0.92 | CTSB (0.58) | CTSBADRB3ADRA2BADRA2CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1455809-B1 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-15 | — | — | EP | disclosed |
| US-6867185-B2 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-20040038872-A1 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038872-A1 | Inhibitors of hepatitis C virus | HAVCR2, LIPC, ZC3HAV1 | CTSB 138/4885ADRB3 3720/4885ADRA2B 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.